Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with mTORC1/2 inhibition. In arm B2 of the National Lung Matrix Trial 54 patients with NSCLC received vistusertib, of which 49 were STK11-deficient (30 with KRAS mutation (B2D), 19 without (B2S)). Objective response (OR) and durable clinical benefit (DCB) rates with 95% credible intervals (CrI) were estimated from posterior probability distributions generated using Bayesian beta-binomial conjugate analysis. In B2D, 2 per-protocol patients obtained OR (estimated true OR rate (95%CrI) 9.8% (2.4-24.3). Estimates of true DCB rate (95%CrI): B2D 24.4% (11.1-42.3), B2S 14.6% (3.6-34.7). Overall, vistusertib cannot be recommended in this context. Longitudinal ctDNA analysis demonstrates enrichment of SMARCA4 mutations post-treatment. In vitro studies show adaptive resistance to mTORC1/2 inhibition via AKT reactivation. (NCT02664935, ISRCTN38344105, EudraCT 2014-000814-73, 10 June 2015).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897347 | PMC |
| http://dx.doi.org/10.1038/s41698-025-00838-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changes in Melanoma Cell Morphology Following Inhibition of Cell Invasion by Third-Generation mTOR Kinase Inhibitors.
Int J Mol Sci
August 2025
John Paul II Hospital, ul. Prądnicka 80, 31-202 Kraków, Poland.
Melanoma is one of the most invasive skin cancers with the highest mortality risk. The PI3K/AKT/mTOR signaling pathways are a key regulatory point related to growth factors and involved in the cell's energy metabolism. They are responsible for cell life processes such as growth, proliferation, invasion, survival, apoptosis, autophagy, and angiogenesis.
View Article and Find Full Text PDFFlotillin-1 promotes the progression of hepatocellular carcinoma by activating TFE3-mediated Golgi stress response inhibition of mTORC1/2.
World J Gastroenterol
August 2025
Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
Background: It is critical to explore effective therapeutic targets for improving the survival rate of patients with hepatocellular carcinoma (HCC). Although many studies have focused on flotillin-1 (FLOT1) as a lipid raft-associated protein that regulates the activation of some proteins or kinases to promote tumor cell survival and proliferation, few studies have explored the regulation of Golgi apparatus function.
Aim: To investigate the molecular mechanism through which FLOT1 activates the Golgi stress response downstream of transcription factor E3 (TFE3), thereby promoting the progression of HCC.
Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models.
Acad Oncol
June 2025
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
We investigated the growth-inhibitory activity of the pan-AKT inhibitor ipatasertib in combination with other targeted therapies. Thirty-nine patient-derived cancer cell lines from the NCI Patient-Derived Models Repository and nine NCI-60 tumor cell lines were grown as mct-spheroids. The mct-spheroids, a mixture of tumor cells (60%), endothelial cells (25%), and mesenchymal stem cells (15%), were established for 3 days before compounds(s) were added.
View Article and Find Full Text PDFCapacity for Compensatory Cyclin D2 Response Confers Trametinib Resistance in Canine Mucosal Melanoma.
Cancers (Basel)
July 2025
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Mucosal melanoma (MM) is a poorly responsive, rare and aggressive subtype with few cases having targetable recurrent driver mutations, although Ras/MAPK and PI3K/AKT/mTOR signaling pathway activations are common. Eventual tumor evasion of targeted therapy continues to limit treatment success. Adequate models are necessary to address therapeutic resistance.
View Article and Find Full Text PDFConcerted inhibition of mTORC1/2 and NF-κB by Yuye Jiedu granule via AMPK activation and PI3K/Akt suppression: A novel therapeutic strategy against upper respiratory infections.
J Ethnopharmacol
July 2025
Institute of Innovative Chinese Medicine, Hunan Academy of Chinese Medicine, Changsha, 410013, China. Electronic address:
Ethnopharmacological Relevance: Yuye Jiedu Granule (YYJD), a traditional herb preparation developed by Hunan Changde Sanjin Pharmaceutical Co., Ltd., has been used in clinical settings for many years to manage upper respiratory tract infections (URTI) attributed to exogenous wind-heat.
View Article and Find Full Text PDF